Factors Influencing Frontline Therapy Options for Favorable-Risk RCC
Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.
Key Considerations for Selecting Frontline Therapy in Advanced RCC
Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.
Neoadjuvant Cabozantinib Enables Resection of Advanced RCC If Timed Properly
Naomi B. Haas, MD, discusses the use of VEGF tyrosine kinase inhibitors as neoadjuvant therapy for renal cell carcinoma.
Exploring New Treatment Options in Prostate Cancer Landscape
Naomi Haas, MD, discusses the current areas of ongoing research in the treatment landscape for patients with prostate cancer.
PSMA Plays Important Role in the Detection of Prostate Cancer
Naomi Haas, MD, discusses the importance of using PSMA, an antigen that is expressed on the cell surface, for the detection of prostate cancer.